Search
Gliclazide
go.drugbank.com/drugs/DB01120ApprovedInvestigationalGliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.
Categories: Drugs Used in DiabetesProducts: Gliavis IR Tablet 80mgPhenylalanine
go.drugbank.com/drugs/DB00120ApprovedInvestigationalNutraceuticalPhenylalanine is an essential aromatic amino acid that is a precursor of melanin, [dopamine], [noradrenalin] (norepinephrine), and [thyroxine].
Mixtures: Aminosyn II in Dextrose, Aminosyn II in DextroseIodide I-131
go.drugbank.com/drugs/DB09293ApprovedInvestigationalBecause the thyroid gland naturally takes up iodine from the body, therapeutic methods using radioisotopes can take advantage of this mechanism for localization of drug to the site of malignancy. … Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine.
Salts: Sodium iodide I-131Synonyms: 131 I, 131-IRamipril
go.drugbank.com/drugs/DB00178ApprovedInvestigationalRamipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. … Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).
Products: RAMIPRIL IG FARMACEUTICI, Van-ramiprilNuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigational[L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399] … [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada.
Pergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnThe drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. … It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors.
Categories: Adrenergic alpha-1 Receptor Agonists, Serotonin Receptor AgonistsBlack cohosh
go.drugbank.com/drugs/DB13975Approved[A32543] The American College of Obstetrics and Gynecology guidelines on the use of botanicals, such as black cohosh, for the management of menopausal symptoms the use of for up to six months, especially … [L2303] Hormone replacement therapy (HRT) is the standard treatment for early symptoms in post-menopausal women, however, increases the risk of stroke, heart diseases, as well as breast cancer in older
Strontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnAvailable for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and, simultaneously, reduces the resorption of bone by osteoclasts.
Mixtures: STRODAY D3 2G/800 IU SAŞE , 28 SAŞE, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADETSodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] The treatment effect was maintained for up to 12 months.[L2933] … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that
Categories: Compounds used in a research, industrial, or household settingOpium
go.drugbank.com/drugs/DB11130ApprovedIllicitThis plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. … Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium.